Unilife — Q3 2012 Earnings Presentation
18 slides from Unilife's earnings presentation, Apr 26, 2012
Slide 1: Third Quarter 2012 Earnings Conference Call
Third Quarter 2012 Earnings Conference Call April 26, 2012 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our mana
Slide 3: Corporate Overview
Corporate Overview Alan Shortall Chief Executive Officer
Slide 4: Making rapid progress to build shareholder value on all fronts
Corporate Update Making rapid progress to build shareholder value on all fronts Strengthening commercial pipeline across multiple customers Commercial supply contracts for Unifill syringe on track from mid-year Significant activity across all device platforms Increased expenditure for March Quarter
Slide 5: A Diversified, Differentiated Portfolio
A Diversified, Differentiated Portfolio Unifill Unitract Auto-Infusors Unifill Select Rita Auto Injector EZMix
Slide 6: The Unifill syringe
The Unifill syringe Continued supply to current and new customers Anticipated signing of supply contracts from 2nd half of 2012 Increasing production capacities in line with market demands
Slide 7: AutoInfusors
AutoInfusors Wearable, disposable devices for subcutaneous self- administration of large volume doses (i.e. 2mL to 15mL) Platform expanding rapidly in response to customer demands Supplied to multiple parties for evaluations and user studies Expect to enter commercial partnerships for human clinical
Slide 8: Specialized Devices
Specialized Devices First GMP-compliant batch of first specialized device for targeted organ delivery ready to be shipped Global pharmaceutical company to use device in human clinical drug trials scheduled to occur later this year Unilife recognized revenue of $566,000 during the March Quarter as pa
Slide 9: Drug Reconstitution Delivery Systems
Drug Reconstitution Delivery Systems Only multi-chamber prefilled reconstitution syringe with integrated safety Minimal steps for reconstitution and injection compared to conventional systems Many emerging opportunities for use with liquid-dry and liquid-liquid combinations EZMix Dual or Multi-Chamb
Slide 10: Rita Auto-Injector
Rita Auto-Injector Single-use disposable system for patient self- injection Only auto-injector with true end-of-dose indicators (audible, tactile, visual) Compact size relative to conventional devices Strong market interest Various customization options Unilife Rita Conventional Auto-Injector
Slide 11: R&D Investment Driven by Customer Needs
R&D Investment Driven by Customer Needs SG&A has remained flat to down reflecting cash conservatism R&D investment reflects: Market demand and commercial interest Continual development of our product pipeline Many development programs in line for partner funding
Slide 12: Financial Data Overview
Financial Data Overview Rich Wieland Chief Financial Officer
Slide 13: Financial Data - Fiscal 3rd Quarter 2012
Revenues for the quarter of $1.3M, compared to $0.7M for 3Q 2011 Industrialization and development fees increased $0.6M related to the clinical development and supply of a novel device for targeted organ delivery Financial Data - Fiscal 3rd Quarter 2012
Slide 14: Financial Data - Fiscal 3rd Quarter 2012 Continued
Net loss for the quarter was $14.9M, or $0.21 per diluted share, compared to a net loss of $12.5M, or $0.20 per diluted share for 3Q 2011 R&D expenses increased by $3.9M due to additional payroll costs and expenditures related to the development of additional advanced drug delivery devices Partially
Slide 15: Financial Data - Fiscal 3rd Quarter 2012 Continued
Adjusted net loss of $10.7M, or $0.15 per diluted share, compared to an adjusted net loss of $9.3M, or $0.15 per diluted share for 3Q 2011 Excludes approx. $4.2M in non-cash share-based compensation expense, depreciation and amortization and interest expense compared to $3.2M in non-cash items in 3Q
Slide 16: Looking Forward
Looking Forward Alan Shortall Chief Executive Officer
Slide 17: Looking Forward
Committed to drive shareholder value by: Building partnerships with an expanding network of customers Accelerating commercialization of our diversified device portfolio Expanding production capabilities in-line with customer demands Investing in R&D and production while keeping SG&A flat On track to
Slide 18: Questions
Questions